HBV Capsid Assembly Modulators for Viral Load Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis B virus (HBV) infection are limited by drug resistance, low efficacy, and tolerability issues, with a need for novel therapeutic agents that can effectively inhibit HBV replication and prevent disease progression.
Innovation Solution
Development of novel antiviral compounds, specifically those of Formula (I), which inhibit HBV proteins and interfere with the HBV life cycle by disrupting capsid assembly and disassembly, leading to antiviral effects such as disruption of virion assembly and reduction in viral load.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments (interferon and nucleoside analogues) are used to suppress HBV DNA, then viral replication is inhibited, but drug resistance develops and efficacy is limited
Solution Approach 1:
The patent introduces capsid assembly modulators (CAMs) as intermediary compounds that disrupt the viral capsid assembly process. These compounds act as mediators between the host cell and the virus, preventing proper capsid formation without directly inhibiting viral polymerase, thereby avoiding the resistance issues associated with current nucleoside analogue treatments
Solution Approach 2:
The patent employs compounds that induce aberrant capsid formation by altering the physical-chemical parameters of capsid assembly. The CAMs change the conformational parameters and assembly kinetics of capsid proteins, leading to non-functional viral particles that cannot complete the replication cycle, providing a novel mechanism of action distinct from current therapies
2Reliability
If current treatments are administered chronically to suppress viral replication, then disease progression is slowed, but treatment duration is prolonged and tolerability issues arise
Solution Approach 1:
The patent utilizes compounds that create defective copies of viral capsids through aberrant assembly. These malformed capsid structures serve as non-functional copies that trap viral components and prevent proper viral replication, potentially achieving durable viral suppression with shorter treatment durations compared to current chronic therapy requirements
3Reliability
If capsid assembly is disrupted to achieve antiviral effects, then viral load is reduced, but normal capsid function is interfered with
Solution Approach 1:
The patent converts the harmful effect of capsid disruption into a beneficial antiviral mechanism. By inducing aberrant capsid assembly, the compounds create non-functional viral particles that cannot complete replication, effectively using the disruption of normal capsid function as the therapeutic mechanism itself to reduce viral load and achieve antiviral activity
Data Source
AI summary
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof:which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.